Skip to main content

AKT Quiz

Quiz
03/11/2024
Study results indicated that the addition of capivasertib to fulvestrant improved PFS from 3.6 months to ____ months.
Study results indicated that the addition of capivasertib to fulvestrant improved PFS from 3.6 months to ____ months.
Study results indicated that the...
03/11/2024
Oncology
Quiz
02/20/2024
True or False: Results from the CAPITELLO-292 study demonstrated that capivasertib plus fulvestrant was safe and tolerable among patients with HR-positive, HER2-negative advanced breast cancer.
True or False: Results from the CAPITELLO-292 study demonstrated that capivasertib plus fulvestrant was safe and tolerable among patients with HR-positive, HER2-negative advanced breast cancer.
True or False: Results from the...
02/20/2024
Oncology
Quiz
02/12/2024
Which dose level of capivasertib plus palbociclib and fulvestrant was most tolerable among patients with heavily pretreated, HR-positive, HER2-negative, advanced breast cancer?
Which dose level of capivasertib plus palbociclib and fulvestrant was most tolerable among patients with heavily pretreated, HR-positive, HER2-negative, advanced breast cancer?
Which dose level of capivasertib...
02/12/2024
Oncology